tbuckley/cabot-search huggingface dataset:
Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients &gt; 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Maria Alma Rodriguez, Michelle Fanale, Fredrick Hagemeister, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Larry Kwak, Luis Fayad, Xuelin Huang, Jean Bernard Durand
Journal: Blood (2007)
TMOD-09DISTINCT TUMOR PHENOTYPES FROM NEURAL PROGENITOR CELL-DERIVED TUMORS
Authors: Olle Lindberg, Andrew McKinney, Jane Engler, Joanna Phillips
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) is a heterogeneous disease and can exhibit a diversity of cell behaviors and responses to therapy, even when driven by a similar set of oncogenic alterations. Using a murine model for glioma based on the genetic manipulation of neural progenitor cells, we asked whether heterogeneous tumors with different tumor cell behaviors and malignancy could be generated using the same oncogenic driver. We established two tumor progenitor cell (TPC) clones with different survival, an aggressive line with short survival (TPC-S) and a less aggressive line with longer survival (TPC-L). Both TPC clones formed invasive tumors in vivo, however with distinct invasive features. TPC-S cells invaded as cohesive clusters, whereas TPC-L cells invaded diffusely, as single cells. Gene expression analysis, proliferation assays, flow cytometry, and cell differentiation assays, were used to define these two cell populations. Aggressive TPC-S cells expanded at almost twice the rate of TPC-L cells in vitro and were enriched for genes associated with DNA proliferation. TPC-S cells had high expression of neural stem/progenitor cell markers, including Prom1 and Id1 compared to TPC-L. Interestingly, the two lines exhibited differences in differentiation capacity with TPC-S cells unable to differentiate in vitro, while TPC-L cells readily formed both Tuj1 and GFAP expressing cells. In the current project we demonstrate how cells with the same oncogenic driver can give rise to tumors with vastly different properties, reflective of different GBM phenotypes. These lines are being used to examine tumor heterogeneity in both mechanistic and preclinical studies.
Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients.
Authors: Vivian Oehler, S. Branford, E. Pogosova-Agadjanyan, N. Shah, C. Sawyers, M. Mao, P. Linsley, T. Hughes, J. Radich
Journal: Blood (2005)
Neurotensin‐Conjugated Reduced Graphene Oxide with Multi‐Stage Near‐Infrared‐Triggered Synergic Targeted Neuron Gene Transfection In Vitro and In Vivo for Neurodegenerative Disease Therapy
Authors: Tsung‐Ying Hsieh, Wei‐Chen Huang, Yi‐Da Kang, Chao‐Yi Chu, Wen‐Lin Liao, You‐Yin Chen, San‐Yuan Chen
Journal: Advanced Healthcare Materials (2016)

Delivery efficiency with gene transfection is a pivotal point in achieving maximized therapeutic efficacy and has been an important challenge with central nervous system (CNS) diseases. In this study, neurotensin (NT, a neuro‐specific peptide)‐conjugated polyethylenimine (PEI)‐modified reduced graphene oxide (rGO) nanoparticles with precisely controlled two‐stage near‐infrared (NIR)‐laser photothermal treatment to enhance the ability to target neurons and achieve high gene transfection in neurons. First‐stage NIR laser irradiation on the cells with nanoparticles attached on the surface can increase the permeability of the cell membrane, resulting in an apparent increase in cellular uptake compared to untreated cells. In addition, second‐stage NIR laser irradiation on the cells with nanoparticles inside can further induce endo/lysosomal cavitation, which not only helps nanoparticles escape from endo/lysosomes but also prevents plasmid DNA (pDNA) from being digested by DNase I. At least double pDNA amount can be released from rGO‐PEI‐NT/pDNA under NIR laser trigger release compared to natural release. Moreover, in vitro differentiated PC‐12 cell and in vivo mice (C57BL/6) brain transfection experiments have demonstrated the highest transfection efficiency occurring when NT modification is combined with external multi‐stage stimuli‐responsive NIR laser treatment. The combination of neuro‐specific targeting peptide and external NIR‐laser‐triggered aid provides a nanoplatform for gene therapy in CNS diseases.
Effect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserin
Authors: Chunyi Zhao, Peng Quan, Chao Liu, Qiaoyun Li, Liang Fang
Journal: Acta Pharmaceutica Sinica B (2016)

The purpose of this study was to investigate the effect of isopropyl myristate (IPM), a penetration enhancer, on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserin. The patches were prepared with DURO-TAK® 87-2287 as a pressure-sensitive adhesive (PSA) containing 5% (w/w) of blonanserin and different concentrations of IPM. An in vitro release experiment was performed and the adhesive performance of the drug-in-adhesive patches with different concentrations of IPM was evaluated by a rolling ball tack test and a shear-adhesion test. The glass transition temperature (Tg) and rheological parameters of the drug-in-adhesive layers were determined to study the effect of IPM on the mechanical properties of the PSA. The results of the in vitro release experiment showed that the release rate of blonanserin increased with an increasing concentration of IPM. The rolling ball tack test and shear-adhesion test showed decreasing values with increasing IPM concentration. The results were interpreted on the basis of the IPM-induced plasticization of the PSA, as evidenced by a depression of the glass transition temperature and a decrease in the elastic modulus. In conclusion, IPM acted as a plasticizer on DURO-TAK® 87-2287, and it increased the release of blonanserin and affected the adhesive properties of the PSA.
Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute
Authors: Ian W. Flinn, R. Seth Cooper, Dana S. Thompson, Jamie K. Waselenko, James Reeves, Rudolph L. Wise, John D. Hainsworth, Jesus G. Berdeja
Journal: Blood (2012)
Supporting the urban poor to quit tobacco: adding years to lives
Authors: Kamran Siddiqi, Helen Elsey
Journal: Thorax (2016)

Tobacco use is in decline in most high-income countries (HICs); however, the number of tobacco users are rising in many low/middle-income countries (LMICs).1 Consequently, by 2030 tobacco-attributable deaths are projected to rise to 8.3 million per year with more than 80% occurring in LMICs.1 Furthermore, the tobacco-attributable burden is not evenly distributed within these nations; being highest in socioeconomically disadvantaged and marginalised sections of society.2 The urban poor—the participants of the trial published by Sarkar et al 3 in Thorax —are particularly vulnerable. For example, 55% of the poorest 20th centile of urban male residents in South Asia use tobacco in contrast to 40% of the richest.4 Quitting tobacco leads to immediate benefits and if stopped before the age of 40, the associated risk of death is reduced by 90%.5 However, tobacco being an addictive substance, most users struggle to quit and many only do so with behavioural and/or pharmacological support.6 According to Global Adult Tobacco Survey, more than 30% of smokers in LMICs attempted to quit in the previous year (15% in China).7 However, in most countries in particular LMICs, cessation advice or services are not available.8 Even where they are, the urban poor are least likely to receive cessation advice …
The Role of High Dose Chemotherapy/Autologous Stem Cell Transplantation for Salvage Treatment for Relapsed Peripheral T Cell Lymphoma.
Authors: Yoojin Cho, Myoung Joo Kang, Dae Ro Choi, Eun Kyoung Kim, Shin Kim, Dae Ho Lee, Sang We Kim, Jooryung Huh, Jeong Shin Lee, Cheolwon Suh
Journal: Blood (2009)
High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy–Treated Patients—Results from a Population-Based Breast Cancer Cohort
Authors: Karin Elebro, Signe Borgquist, Ann H. Rosendahl, Andrea Markkula, Maria Simonsson, Karin Jirström, Carsten Rose, Christian Ingvar, Helena Jernström
Journal: Clinical Cancer Research (2016)

Isoform-specific tumor estrogen receptor β (ERβ) expression may hold prognostic information in breast cancer, especially among endocrine-treated breast cancer patients. The study's purpose was to evaluate ERβ isoform 1 (ERβ1) expression in relation to tumor characteristics, ESR2 genotypes, and prognosis in different treatment groups.A population-based prospective cohort of 1,026 patients diagnosed with primary invasive breast cancer in Lund, Sweden, between October 2002 and June 2012 was followed until June 2014 (median 5 years). Associations between immunohistochemical ERβ1 expression, patient and tumor characteristics, as well as outcome within treatment groups were analyzed.Tumor ERβ1 expression was available for 911 patients (89%) and was not associated with ESR2 genotypes. ERβ1 positivity, defined as >75% (ERβ175+, 72.7%), was positively associated with established favorable tumor characteristics. Overall, ERβ175+ was associated with lower risk of breast cancer events [HRadj = 0.60; 95% confidence interval (CI), 0.41-0.89]. The magnitude of the association was larger in patients with ERα- tumors (HRadj = 0.30; 95% CI, 0.12-0.76), compared with ERα+ tumors (HRadj = 0.66; 95% CI, 0.42-1.03). Among the 232 chemotherapy-treated patients, ERβ175+ tumors were associated with lower risk of breast cancer events compared with ERβ175- tumors (HRadj = 0.31; 95% CI, 0.15-0.64). Among the 671 chemonaïve patients, ERβ175 status was not associated with the outcome.High ERβ1 expression was a favorable prognostic marker in this breast cancer cohort, especially in chemotherapy-treated patients, but not in endocrine therapy-treated patients. These results warrant confirmation, preferably via a biomarker study in a previously conducted randomized trial. Clin Cancer Res; 23(3); 766-77. ©2016 AACR.
Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY
Authors: Silva Arslanian, Laure El ghormli, Fida Bacha, Sonia Caprio, Robin Goland, Morey W. Haymond, Lynne Levitsky, Kristen J. Nadeau, Neil H. White, Steven M. Willi
Journal: Diabetes Care (2016)

OBJECTIVE The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined—metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle—were higher in non-Hispanic blacks (NHB; 52.8%) versus non-Hispanic whites (NHW; 36.6%) and Hispanics (H; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity. RESEARCH DESIGN AND METHODS TODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA). RESULTS At baseline NHB had significantly lower HMWA than NHW and H and exhibited a significantly smaller increase (17.3% vs. 33.7% vs. 29.9%, respectively) during the first 6 months overall. Increases in HMWA were associated with reductions in glycemic failure in the three racial/ethnic groups combined (hazard ratio 0.61, P &amp;lt; 0.0001) and in each race/ethnicity separately. Over time, HMWA was significantly lower in those who failed versus did not fail treatment, irrespective of race/ethnicity. There were no differences in treatment-associated temporal changes in insulin sensitivity, C-peptide index, and oDI among the three racial/ethnic groups. CONCLUSIONS HMWA is a reliable biomarker of treatment response in youth with type 2 diabetes. The diminutive treatment-associated increase in HMWA in NHB (∼50% lower) compared with NHW and H may explain the observed racial/ethnic disparity with higher therapeutic failure rates in NHB in TODAY.
GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Has Antitumor Activity Against Naive and Melphalan-Refractory Spontaneous Myeloma in Pet Dogs.
Authors: Douglas H. Thamm, Daniel B. Tumas, Hans Reiser, Grushenka H.I. Wolfgang, Ilene D. Kurzman, Susan Plaza, Christie Anderson, Cecilia Robat, David M. Vail
Journal: Blood (2007)
Histological Characteristics of Ataxia Telangiectasia Associated Lymphoproliferative Diseases. Results of the French Registry of Primary Immune Deficiencies
Authors: Danielle Canioni, Nizar Mahlaoui, Chantal Andriamanga, Catherine Dubois d'Enghien, Jean-Philippe Jais, Alain Fischer, Olivier Hermine, Nicole Brousse, Dominique Stoppa-Lyonnet, Felipe Suarez
Journal: Blood (2014)
Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents
Authors: Stephanie Harel, Sophie Bernard, Sylvie Chevret, Regis Peffault de Latour, Lionel Karlin, Marie Robin, Lionel Ades, Raphael Szalat, Marion Malphette, Bouchra Asli, Jean Paul Fermand, Bertrand Arnulf, Gerard Socie
Journal: Blood (2012)
Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.
Authors: Emanuela Carlotti, David Wrench, Sameena Iqbal, Derville O’Shea, Andrew Davies, Priya Virappane, Jason Hart, Raymond Lai, John G. Gribben, Andrew T. Lister, Jude Fitzgibbon
Journal: Blood (2007)
Different Isoforms of BSAP Protein Regulate the Expression of Activation-Induced Cytidine Deaminase (AID) in Normal and CLL B-Cells.
Authors: Pablo J. Oppezzo, Gerard M. Dumas, Ana Ines Lalanne, Otto F. Pritsch, Francoise M. Vuillier, Guillaume J. Dighiero
Journal: Blood (2004)
Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.
Authors: Hazem A. Sayala, Paul Moreton, Ben Kennedy, Guy Lucas, Michael Leach, Saad M.B. Rassam, Andrew Haynes, Jane Tighe, David G. Oscier, Christopher Fegan, Andy C. Rawstron, Peter Hillmen
Journal: Blood (2007)
The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.
Authors: Sara C. Meyer, Carlo R. Largiader, Shengyu Jin, X. Long Zheng, Clemens A. Dahinden, James N. George, Bernhard Lammle, Johanna A. Kremer Hovinga
Journal: Blood (2007)
Metastatic synovial sarcoma of lung mimicking pulmonary embolism and deep venous thrombosis
Authors: Jiaojiao Qiu, Wanmu Xie, Zhenguo Zhai, Jun Wan, Chen Wang
Journal: Thorax (2016)

Synovial sarcoma (SS) is a highly aggressive mesenchymal malignancy that usually originates from deep soft tissues of the extremities. Lungs are the most common metastatic site, but rare cases of vascular metastasis have been reported. Here we report a case of metastatic SS in a 26-year-old male patient with right lower extremity oedema first misdiagnosed as deep venous thrombosis (DVT). CT pulmonary angiogram (CTPA) revealed a mass lesion inside the right pulmonary artery mimicking PE. The diagnosis of SS was established by histopathological examination acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from the right pulmonary artery. 18FDG-PET revealed that breviductor and pectineus muscle was the original site of SS with metastasis in common and external iliac veins, pulmonary artery and pulmonary parenchyma.

A 26-year-old man presented to our hospital with repeated right leg swelling and chest pain. Nine months before hospitalisation, the patient had right leg swelling and was diagnosed with DVT according to an ultrasound scan. Catheter-directed thrombolysis was performed followed by anticoagulation. The patient had slight relief in symptoms. Seven months later he had intermittent chest pain. …
Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole.
Authors: Steven Trifilio, Judy Pi, Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Jane Winter, Stephanie Williams, Jayesh Mehta
Journal: Blood (2007)
Identification of SCL and LMO Oncogenes as Transcriptional Repressors of HEB/E2A in the Thymus through Functional Genomic/Genetic Approaches.
Authors: Mathieu Tremblay, Sabine Herblot, Margarita Todorova, Veronique Lisi, Francois Major, Sebastien Lemieux, Trang Hoang
Journal: Blood (2007)
O098 : Long term NLRP3 inflammasome activation leads to severe liver fibrosis via inflammatory macrophage polarization and direct activation of hepatic stellate cells
Authors: A. Wree, M.D. McGeough, E. Inzaugarat, C.A. Peña, A. Cherñavsky, H.M. Hoffman, A.E. Feldstein
Journal: Journal of Hepatology (2015)
EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010
Authors: Mansoor N. Saleh, Gregory Cheng, James B. Bussel, Huiping Sun, Bhabita Mayer, Christine Bailey, Andres Brainsky
Journal: Blood (2010)
Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis.
Authors: Francisco Jose Gelpi-Hammerschdmidt, Christopher B. Allard, Benjamin I. Chung, Steven L. Chang
Journal: Journal of Clinical Oncology (2015)

337 Background: Nephroureterectomy (NU) is the standard treatment for upper tract urothelial carcinoma (UTUC). Minimally invasive (MI) laparoscopic or robotic-assisted approaches have been introduced in an effort to reduce morbidity. We performed a population-based study to evaluate contemporary utilization trends, morbidity, and costs associated with NUs in the United States. Methods: Using the Premier Hospital Database (Premier, Inc., Charlotte, NC), a nationally representative discharge database with data from over 600 non-federal hospitals in the United States, we captured patients who underwent a NU (ICD-9 55.51) with diagnoses of renal pelvis (189.1) or ureteral (189.2) neoplasms from 2004 to 2013. We fitted regression models, adjusting for clustering by hospitals and survey weighting to evaluate 90-day postoperative complications, length of stay (LOS), OR time, and direct hospital costs among open, laparoscopic, and robotic NU. Results: The weighted cohort included 17,245 open, 13,298 laparoscopic, and 3,745 robotic NUs. MI surgeries increased from 36% to 54% from 2004 to 2013, while the number of NUs decreased by nearly 20% during the same period (Figure 1). The overall 90-day mortality, major (Clavien 3-5), and minor (Clavien 1-2) complication rates were 1.89%, 9.4%, and 27.7%, respectively, with no statistically significant differences between the three approaches based on adjusted logistic regression analyses. The LOS was decreased for laparoscopic (Incidence Risk Ratio [IRR]: 0.87, 95% CI: 0.82-0.92, p&lt;0.001) and robotic (IRR: 0.76, 95% CI: 0.7-0.83, p&lt;0.001) NU compared to open NU. OR time was 10.35 (p&lt;0.05) and 56.35 (p&lt;0.001) minutes longer for laparoscopic and robotic NU. Adjusted 90-day median direct hospital costs were $1,354 and $3,533 higher for laparoscopic and robotic NU (p&lt;0.001). Conclusions: During this contemporary 10-year study, the use of MI NUs increased to over half of procedures with a recent surge in robotic NUs, along with a concurrent reduction in total NUs performed in the United States. Comparable perioperative outcomes suggest that the morbidity profile may be driven primarily by patient-specific characteristics as opposed to surgical approach.
The Use of Intravenous Compared with Oral Busulfan in High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for Lymphoma Is Associated with Improved Relapse-Free Survival.
Authors: Robert Dean, Brad Pohlman, John William Sweetenham, Ronald Sobecks, Matt Kalaycio, Steven Andresen, Lisa Rybicki, Christopher Lowe, Stacey Brown, Julie Curtis, Brian Bolwell
Journal: Blood (2006)
In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).
Authors: Rebecca M. Ricklis, Judith E. Karp, Eric J. Feldman, Suzanne Galkin, Jacqueline M. Greer, Valerie Ironside, Kim Mirjafary, Timothy D. Talbot, Lawrence E. Morris, John J. Wright, Scott H. Kaufmann
Journal: Blood (2007)
Hyaluronic Acid/PLGA Core/Shell Fiber Matrices Loaded with EGCG Beneficial to Diabetic Wound Healing
Authors: Yong Cheol Shin, Dong‐Myeong Shin, Eun Ji Lee, Jong Ho Lee, Ji Eun Kim, Sung Hwa Song, Dae‐Youn Hwang, Jun Jae Lee, Bongju Kim, Dohyung Lim, Suong‐Hyu Hyon, Young‐Jun Lim, Dong‐Wook Han
Journal: Advanced Healthcare Materials (2016)

During the last few decades, considerable research on diabetic wound healing strategies has been performed, but complete diabetic wound healing remains an unsolved problem, which constitutes an enormous biomedical burden. Herein, hyaluronic acid (HA)/poly(lactic‐ co ‐glycolic acid, PLGA) core/shell fiber matrices loaded with epigallocatechin‐3 ‐O‐ gallate (EGCG) (HA/PLGA‐E) are fabricated by coaxial electrospinning. HA/PLGA‐E core/shell fiber matrices are composed of randomly‐oriented sub‐micrometer fibers and have a 3D porous network structure. EGCG is uniformly dispersed in the shell and sustainedly released from the matrices in a stepwise manner by controlled diffusion and PLGA degradation over four weeks. EGCG does not adversely affect the thermomechanical properties of HA/PLGA‐E matrices. The number of human dermal fibroblasts attached on HA/PLGA‐E matrices is appreciably higher than that on HA/PLGA counterparts, while their proliferation is steadily retained on HA/PLGA‐E matrices. The wound healing activity of HA/PLGA‐E matrices is evaluated in streptozotocin‐induced diabetic rats. After two weeks of surgical treatment, the wound areas are significantly reduced by the coverage with HA/PLGA‐E matrices resulting from enhanced re‐epithelialization/neovascularization and increased collagen deposition, compared with no treatment or HA/PLGA. In conclusion, the HA/PLGA‐E matrices can be potentially exploited to craft strategies for the acceleration of diabetic wound healing and skin regeneration.
Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21.
Authors: Cecele J Denman, Lisa M. Kopp, Vladimir Senyukov, Sarah Hagemeister, Jennifer Johnson, Maria A Lima Da Silva, Harjeet Singh, Lenka Hurton, Simon Olivares, Mary Helen Huls, Richard E Champlin, Laurence J.N. Cooper, Dean A. Lee
Journal: Blood (2009)
Relief for Ear Pain
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal